Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) belongs to Healthcare sector. Its weekly performance is 17.80%. On last trading day company shares ended up $13.90. Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) distance from 50-day simple moving average (SMA50) is 10.14%.Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) announced that it has received advice from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) with regard to the clinical and regulatory aspects of Dipexium’s planned submission of a Marketing Authorization Application (MAA) for Locilex® for topical treatment of patients with diabetic foot infection (DFI) in European Union.
QUALCOMM, Inc. (NASDAQ:QCOM) shares moved down -0.10% in last trading session and ended the day at $69.35. QCOM Gross Margin is 60.30% and its return on assets is 14.90%. QUALCOMM, Inc. (NASDAQ:QCOM) quarterly performance is -2.21%. QUALCOMM, Inc. (NASDAQ:QCOM) said that its subsidiary, Qualcomm Atheros, Inc., is unveiling new 802.11ac Wave 2 solutions that combine multi-user multi-input/multi-output (MU-MIMO), support for 160 MHz channels and 4×4 antenna configurations to offer higher performance and more efficient Wi-Fi connectivity.
On 02 June, NVE Corp. (NASDAQ:NVEC) shares moved down -0.17% and was closed at $71.65. NVEC EPS growth in last 5 year was 3.60%. NVE Corp. (NASDAQ:NVEC) year to date (YTD) performance is 5.88%. Zacks upgraded shares of NVE Corp. (NASDAQ:NVEC) from a hold rating to a buy rating in a research note issued to investors on Monday. The firm currently has $79.00 price target on the stock.
Dynavax Technologies Corporation (NASDAQ:DVAX) ended the last trading day at $21.89. Company weekly volatility is calculated as 3.77% and price to cash ratio as 6.57. Dynavax Technologies Corporation (NASDAQ:DVAX) showed a weekly performance of -0.73%. On 1 June, Dynavax Technologies Corporation (NASDAQ:DVAX) and Merck & Co. Inc announced that they have entered into two clinical trial collaboration agreements to investigate the potential synergistic effect of combining immunotherapies from both companies’ pipelines: Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), and its investigational anti-interleukin-10 (anti-IL-10) immunomodulator, MK-1966, with Dynavax’s investigational toll-like receptor 9 (TLR9) agonist, SD-101.
Threshold Pharmaceuticals Inc. (NASDAQ:THLD) shares moved down -1.82% in last trading session and ended the day at $3.77. THLD return on assets is -32.40%. Threshold Pharmaceuticals Inc. (NASDAQ:THLD) quarterly performance is -17.51%.On 31 May, Threshold Pharmaceuticals Inc. (NASDAQ:THLD) announced new preliminary data from the Phase 2 component of an ongoing Phase 1/2 trial of evofosfamide (an investigational compound formerly known as TH-302) in combination with the proteasome inhibitor Velcade® and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. A clinical benefit rate of 29% (one complete response, two partial responses, and one minimal response) was observed in patients treated at the recommended Phase 2 dose of evofosfamide (340 mg/m2) in EBorD.